AlphaValue Corporate Services
COVERAGE ABOUT US CONTACT FR
This research has been commissioned and paid for by the company and is deemed to constitute an acceptable minor non-monetary benefit as defined in MiFID II

Crossject

CR 		Bloomberg   ALCJ FP
Supergenerics  /  France  Web Site   |   Investors Relation
Things get going
Graphs     Help
Perf. 1W: 2.23%- Perf. 1M: -40.3%- Perf. 3M: -60.3%- Perf Ytd: -58.6%
10 day relative perf. to stoxx600: -4.93%- 20 day relative perf. to stoxx600: -39.1%